姜黄素固体分散体在猪体内的比较药动学研究

doi:10.11843/j.issn.0366-6964.2020.11.024

摘要/Abstract

摘要： 本研究首次建立了测定猪血浆中姜黄素的高效液相色谱串联质谱法（HPLC-MS/MS），比较了在内服给药途径下，姜黄素固体分散体和姜黄素预混剂在仔猪体内的药动学特征。选用16头7周龄左右健康二元杂交猪（约克夏×长白），公母各半，随机分为2组，每组8头，按100 mg·kg^-1（以姜黄素计）分别灌服姜黄素固体分散剂和姜黄素预混剂，不同时间点采集血浆样品，经提取、净化后采用HPLC-MS/MS测定血浆中姜黄素的药物浓度，使用WinNonlin 5.2.1软件非房室模型计算、分析姜黄素在猪体内的药动学参数。结果显示，仔猪灌服姜黄素固体分散体和姜黄素预混剂后的药时曲线下面积（AUC）分别为（104.53±38.67）和（37.82±11.48）h·ng·mL^-1；达峰时间（T_max）分别为（3.25±0.38）和（2.31±0.37）h；峰浓度（C_max）分别为（26.65±9.65）和（9.55±2.75）ng·mL^-1；消除半衰期（t_1/2β）分别为（3.55±2.17）和（6.93±0.86）h；平均驻留时间（MRT）分别为（5.23±0.53）和（4.26±0.47）h，统计分析表明，与预混剂相比，仔猪灌服姜黄素固体分散体后，主要药动学参数差异显著（P<0.01），T_max明显延迟，C_max显著提高，AUC明显增大，姜黄素固体分散体的相对生物利用度为280.39%。结果表明，姜黄素固体分散体可改善姜黄素在肠道的吸收，提高姜黄素的生物利用度，为今后姜黄素固体分散体的开发和临床应用提供科学依据。

关键词: 姜黄素, 固体分散体, 药动学, 断奶仔猪

Abstract: A method for the detection of curcumin in pig plasma by high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) was established firstly and the pharmacokinetics of curcumin solid dispersion and curcumin premix in piglets were studied. Sixteen healthy piglets (Yorkshire×Changbai), seven-week aged, half male and half female, were randomly divided into two groups receiving curcumin solid dispersant and curcumin premix orally at the dose of 100 mg·kg^-1, respectively. Then plasma samples were collected at different time points, and the blood concentration of curcumin was determined by HPLC-MS/MS. The WinNonlin 5.2.1 software was used to analyze and calculate the pharmacokinetic parameters. The pharmacokinetic parameters of curcumin solid dispersion and curcumin premix were as follows: the area under the curve (AUC) was (104.53±38.67) and (37.82±11.48) h·ng·mL^-1, time to peak concentration (T_max) was (3.25±0.38) and (2.31±0.37) h, peak concentration (C_max) was (26.65±9.65) and (9.55±2.75) ng·mL^-1, respectively, elimination half-life time (t_1/2β) was (3.55±2.17) and (6.93±0.86) h, mean residence time (MRT) was (5.23±0.53) and (4.26±0.47) h. The statistical analysis showed significant differentce (P<0.01) between curcumin solid dispersion and premix in parameters, the T_max of curcumin solid dispersion was delayed significantly, the C_max was increased obviously and the AUC was improved after the piglets were given curcumin solid dispersion. Compared with curcumin premix, the relative bioavailability of curcumin solid dispersion was 280.39%. The results showed that curcumin solid dispersion could improve the dissolution and absorption of curcumin in the intestinal tract and improve the relative bioavailability of curcumin, which provided a scientific basis for the development and clinical application of curcumin solid dispersions in the future.

Key words: curcumin, solid dispersion, pharmacokinetic, weaning piglets

中图分类号:

S859.7

刘子瑶, 黄春梅, 许颖, 郭春娜, 黄显会. 姜黄素固体分散体在猪体内的比较药动学研究[J]. 畜牧兽医学报, 2020, 51(11): 2858-2866.

LIU Ziyao, HUANG Chunmei, XU Ying, GUO Chunna, HUANG Xianhui. Pharmacokinetics of Curcumin Solid Dispersion in Piglets[J]. Acta Veterinaria et Zootechnica Sinica, 2020, 51(11): 2858-2866.

参考文献 29

[1]	王涵东, 梁维邦. 姜黄素的研究进展[J]. 江苏医药, 2014, 40(10):1193-1194.WANG H D, LIANG W B. Research progress of curcumin[J]. Jiangsu Medical Journal, 2014, 40(10):1193-1194. (in Chinese)
[2]	秦洛宜. 姜黄、莪术、郁金的化学成分与药理作用研究分析[J]. 临床研究, 2019, 27(2):3-4.QIN L Y. Analysis of chemical constituents and pharmacological effects of turmeric, medlar and turmeric[J]. Clinical Research, 2019, 27(2):3-4. (in Chinese)
[3]	胡文卓, 李杜, 冯玛莉. 姜黄素药理作用的研究进展[J]. 世界最新医学信息文摘, 2017, 17(40):31-33.HU W Z, LI D, FENG M L. Research progress on pharmacological effects of curcumin[J]. World Latest Medicine Information, 2017, 17(40):31-33. (in Chinese)
[4]	苗淑涵, 高晋生. 姜黄素药理作用的研究进展[J]. 光明中医, 2017, 32(15):2284-2287.MIAO S H, GAO J S. Research progress on pharmacological effect of curcumin[J]. Guangming Journal of Chinese Medicine, 2017, 32(15):2284-2287. (in Chinese)
[5]	MENON V P, SUDHEER A R. Antioxidant and anti-inflammatory properties of curcumin[M]//AGGARWAL B B, SURH Y J, SHISHODIA S. The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease. Boston, MA:Springer, 2007:105-125.
[6]	NAGPAL M, SOOD S. Role of curcumin in systemic and oral health:an overview[J]. J Nat Sci Biol Med, 2013, 4(1):3-7.
[7]	ALOK A, SINGH I D, SINGH S, et al. Curcumin-pharmacological actions and its role in oral submucous fibrosis:a review[J]. J Clin Diagn Res, 2015, 9(10):ZE01-ZE03.
[8]	ZOROFCHIAN MOGHADAMTOUSI S, ABDUL KADIR H, HASSANDARVISH P, et al. A review on antibacterial, antiviral, and antifungal activity of curcumin[J]. BioMed Res Int, 2014, 2014:186864.
[9]	TYAGI P, SINGH M, KUMARI H, et al. Bactericidal activity of curcumin I is associated with damaging of bacterial membrane[J]. PLoS One, 2015, 10(3):e0121313.
[10]	LI Y M, WANG J, LIU Y C,et al. Antiviral and virucidal effects of curcumin on transmissible gastroenteritis virus in vitro[J/OL]. J Gen Virol, 2020. (2020-07-17)[2020-08-10]. https://www.microbiologyresearch.org/content/journal/jgv/10.1099/jgv.0.001466#tab2.
[11]	SANMUKHANI J, SATODIA V, TRIVEDI J, et al. Efficacy and safety of curcumin in major depressive disorder:a randomized controlled trial[J]. Phytother Res, 2014, 28(4):579-585.
[12]	李然, 刘晓红, 孔天, 等. 姜黄素的安全性毒理学评价[J]. 卫生研究, 2011, 40(6):747-749.LI R, LIU X H, KONG T, et al. Safety toxicology evaluation of curcumin[J]. Journal of Hygiene Research, 2011, 40(6):747-749. (in Chinese)
[13]	Laurus Labs Private Ltd. GRAS Notice (GRN) No. 822 Curcumin[DB/OL]. 2018. (2018-11-15)[2020-07-10]. https://www.fda.gov/media/132575/download.
[14]	HEWLINGS S J, KALMAN D S. Curcumin:a review of its' effects on human health[J]. Foods, 2017, 6(10):92.
[15]	中华人民共和国农业农村部. 中华人民共和国农业农村部公告第194号[EB]. (2019-07-10)[2020-05-07]. http://www.moa.gov.cn/govpublic/xmsyj/201907/t20190710_6320678.htm. Ministry of Agriculture and Rural Affairs, PRC. Gazette of the Ministry of agriculture of the people's republic of China, No. 194[EB]. http://www.moa.gov.cn/govpublic/xmsyj/201907/t20190710_6320678.htm.
[16]	XUN W J, SHI L G, ZHOU H L, et al. Effects of curcumin on growth performance, jejunal mucosal membrane integrity, morphology and immune status in weaned piglets challenged with enterotoxigenic Escherichia coli[J]. Int Immunopharmacol, 2015, 27(1):46-52.
[17]	BERGINC K, TRONTELJ J, BASNET N S, et al. Physiological barriers to the oral delivery of curcumin[J]. Pharmazie, 2012, 67(6):518-524.
[18]	梁宇飞, 张欣欣, 赵丽艳, 等. 从姜黄素的代谢特点探讨姜黄素与胡椒碱的联合应用[J]. 神经药理学报, 2019, 9(6):47-57.LIANG Y F, ZHANG X X, ZHAO L Y, et al. Discussed the application of curcumin combined with piperine based on the metabolic characteristics of curcumin[J]. Acta Neuropharmacologica, 2019, 9(6):47-57. (in Chinese)
[19]	高华宏. 复方姜黄素分散片的研制及其在家兔体内的药动学研究[D]. 广州:广州中医药大学, 2011.GAO H H. The development of compound curcumin dispersible tablets and the pharmacokinetics study in rabbits[D]. Guangzhou:Guangzhou University of Chinese Medicine, 2011. (in Chinese)
[20]	董春柳,刘艳艳,王天梓,等. 阿苯达唑固体分散体的制备及分析[J]. 畜牧兽医学报, 2014, 45(6):1018-1023.DONG C L,LIU Y Y,WANG T Z,et al. Preparation and analysis of albendazole solid dispersions[J]. Acta Veterinaria et Zootechnica Sinica, 2014, 45(6):1018-1023. (in Chinese)
[21]	许东晖, 王胜, 梅雪婷, 等. 聚乙烯吡咯烷酮K30对姜黄素的增溶作用研究[J]. 中药材, 2008, 31(3):438-442.XU D H, WANG S, MEI X T, et al. Studies on solubility enhancement of curcumin by polyvinyl-pyrrolidione K30[J]. Journal of Chinese Medicinal Materials, 2008, 31(3):438-442. (in Chinese)
[22]	崔福德. 制剂新技术[M]//崔福德. 药剂学. 6版. 北京:人民卫生出版社, 2009:375-396.CUI F D. New preparation technology[M]//CUI F D. Pharmacy. 6th ed. Beijing:People's Medical Publishing House, 2009:375-396. (in Chinese)
[23]	李新建, 刘晓城. 姜黄素调节小鼠免疫功能的实验研究[J]. 中国组织化学与细胞化学杂志, 2005, 14(2):132-135.LI X J, LIU X C. Effect of curcumin on immunological function of the mice[J]. Chinese Journal of Histochemistry and Cytochemistry, 2005, 14(2):132-135. (in Chinese)
[24]	周明, 张靖, 申书婷, 等. 姜黄素在育肥猪中应用效果的研究[J]. 中国粮油学报, 2014, 29(3):67-73.ZHOU M, ZHANG J, SHEN S T, et al. The applied effects of curcumin in finishing swine[J]. Journal of the Chinese Cereals and Oils Association, 2014, 29(3):67-73. (in Chinese)
[25]	BANGPHUMI K, KITTIVIRIYAKUL C, TOWIWAT P, et al. Pharmacokinetics of curcumin diethyl disuccinate, a prodrug of curcumin, in wistar rats[J]. Eur J Drug Metab Pharmacokinet, 2016, 41(6):777-785.
[26]	GUTIERRES V O, CAMPOS M L, ARCARO C A, et al. Curcumin pharmacokinetic and pharmaco-dynamic evidences in streptozotocin-diabetic rats support the antidiabetic activity to be via metabolite(s)[J]. Evid Based Complement Altern Med, 2015, 2015:678218.
[27]	黄秀旺, 许建华, 吴国华, 等. 姜黄素固体分散体在小鼠体内的药代动力学[J]. 中国药理学通报, 2008, 24(11):1525-1527.HUANG X W, XU J H, WU G H, et al. Pharmacokinetics of curcumin solid dispersion in mice[J]. Chinese Pharmacological Bulletin, 2008, 24(11):1525-1527. (in Chinese)
[28]	罗见春, 何丹, 尹华峰, 等. 姜黄素磷脂复合物的药代动力学评价[J]. 第二军医大学学报, 2014, 35(7):754-757.LUO J C, HE D, YIN H F, et al. Pharmacokinetics evaluation of curcumin-phospholipid complex[J]. Academic Journal of Second Military Medical University, 2014, 35(7):754-757. (in Chinese)
[29]	韩刚, 翟丽, 赵琳琳, 等. 姜黄素固体分散体在大鼠体内的药动学研究[J]. 中国药学杂志, 2009, 44(9):698-700.HAN G, ZHAI L, ZHAO L L, et al. Pharmaco-kinetics of curcumin solid dispersion in rats in vivo[J]. Chinese Pharmaceutical Journal, 2009, 44(9):698-700. (in Chinese)